Below you'll find a list of all posts that have been tagged as “Pharmaceutical”
SAN DIEGO, and TOKYO, April 14, 2020 – MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today jointly announced that the companies have entered into a global license, development and commercialization agreement to further develop and commercialize MEI’s ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kδ), in clinical development for …
Edinburgh-based bioinformatics company, Fios Genomics (“Fios”), which helps pharmaceutical and biotech companies to analyse the large amounts of data generated during drug development, has announced a strategic partnership with one of the world’s largest contract research organisations, Charles River Laboratories, (“Charles River”). Through this partnership, Charles River clients worldwide will have access to Fios’s expertise in bioinformatics, statistics and biology …
Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s (EMA) scientific committee, has adopted a Positive Opinion recommending approval of the marketing authorisation of mogamulizumab
MGB Biopharma’s anti-bacterial agent for treatment of C. difficile infections, helped by Archangels funding round, to enter Phase II clinical trials
Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Poteligeo®
PharmaKrysto announces a global licensing deal with Rutgers Universityfor PK10, a potentially revolutionary compound to treat people with cystinuria.
A novel antibiotic, which has been developed in Scotland for the treatment of Clostridium difficile, will take a step closer to being brought to market following the completion of a further round of funding led by prominent angel investment syndicate, Archangels, for MGB Biopharma (MGB).
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), announces that it is to expand its headquarters facility in Galashiels, Scotland, to accommodate the growth of the business. The news comes as KKI reports record turnover of £251m for 2016, growth of 13% over 2015 revenues of £222m. KKI (formerly known as ProStrakan) is a wholly-owned subsidiary of Japan-based Kyowa …
Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency.
Scottish Borders-based pharmaceutical company, Ryboquin Ltd, has raised £1.3m of new funding that will allow the company to take its cancer gene therapy product one step closer to undergoing clinical trials…
ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and AstraZeneca today announced that they have entered into an agreement for ProStrakan to acquire the rights to Moventig® (naloxegol) in the European Union (EU)…
Spreng Thomson: Intelligent Creative Communications
Spreng Thomson is committed to Fair Work, by ensuring that our people have an effective voice, by investing in their development and by not using zero hours contracts.
+44(0)141 548 5191
[email protected]
The Herald Building,
155 Albion Street,
Glasgow G1 1RU, UK
© 2024 Spreng Thomson Limited.
Registered in Scotland No. 173454
